It’s no secret that 2023 has been a year for a shift in thinking when it comes to psychedelics, in particular as pertains to their use for hard-to-treat or treatment resistant mental health
Biotech Sunbird Bio has announced its completed merger with Glympse Bio, which it is hoped will accelerate development of the companies’ protein-based diagnostic technolog
From remote monitoring tech to enable clinical trials, to AI for drug discovery, to digital therapeutics and drugs with companion apps, digital innovation has the potential to touch every c
Biogen has signed a brace of collaborations to expand its central nervous system (CNS) pipeline, adding new candidates for Alzheimer’s, multiple sclerosis and other neurological diseases.
Selective serotonin reuptake inhibitors (SSRIs) are the first-line drug therapy of choice for most people suffering from depression but often fail to work effectively.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.